Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients

Korean Circulation Journal

Volumn 45, Issue 3, 2015, Pages 225-233

  Jang, Ji Yong ^a   Lee, Sang Hak ^a   Kim, Byung Soo ^b   Seo, Hong Seog ^c   Kim, Woo Shik ^d   Ahn, Youngkeun ^e   Lee, Nae Hee ^f   Koh, Kwang Kon ^g   Kang, Tae Soo ^h   Jo, Sang Ho ⁱ   Hong, Bum Kee ^a   Bae, Jang Ho ^j   Yang, Hyoung Mo ^k   Cha, Kwang Soo ^l   Kim, Bum Soo ^m   Kwak, Choong Hwan ⁿ   Cho, Deok Kyu ^o   Kim, Ung ^p   Zo, Joo Hee ^q   Kang, Duk Hyun ^r   Pyun, Wook Bum ^s   Chun, Kook Jin ^t   Namgung, June ^u   Cha, Tae Joon ^v   Juhn, Jae Hyeon ^w   Jung, Yeili ^w   Jang, Yangsoo ^a   more..

^a Yonsei University   (South Korea)

^b Dae Dong Hospital   (South Korea)

^c Korea University   (South Korea)

^d Kyung Hee University   (South Korea)

^e Chonnam National University Medical School   (South Korea)

^f Soonchunhyang University   (South Korea)

^g Gachon University   (South Korea)

^h Dankook University College of Medicine   (South Korea)

ⁱ Hallym University   (South Korea)

^j Konyang University College of Medicine   (South Korea)

^k Ajou University Medical CentSuwon   (South Korea)

^l Pusan National University School of Medicine   (South Korea)

^m Sungkyunkwan University   (South Korea)

ⁿ Gyeongsang National University   (South Korea)

^o Seonam University of Medicine Myongji Hospital   (South Korea)

^p Young Nam University Hospital   (South Korea)

^q Seoul National University   (South Korea)

^r University of Ulsan   (South Korea)

^s Ewha Womans University   (South Korea)

^t Pusan National University Yangsan Hospital   (South Korea)

^u Inje University   (South Korea)

^v Kosin University   (South Korea)

^w LG Chemical Ltd   (South Korea)

more..

Author keywords

Blood pressure; Controlled clinical trials, randomized; Drug therapy, combination; Rosuvastatin; Valsartan

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL; VALSARTAN;

ADULT; ADVERSE OUTCOME; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

EID: 84930399492     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2015.45.3.225     Document Type: Article

References (30)

1. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-6.
2. Thomas F, Bean K, Guize L, Quentzel S, Argyriadis P, Benetos A. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J 2002;23:528-35.
3. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20.
4. Nickenig G, Harrison DG. The AT (1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT (1) receptor regulation. Circulation 2002;105:530-6.
5. Keidar S, Kaplan M, Shapira C, Brook JG, Aviram M. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 1994;107:71-84.
6. Pool JL, Glazer R, Chiang YT, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens 1999;13:275-81.
7. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
8. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
9. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889-934.
10. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42:963-70.
11. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000;35:549-55.
12. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-6.
13. Sposito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensinconverting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999;83:1497-9, A8.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
15. Cifkova R, Erdine S, Fagard R, et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003;21:1779-86.
16. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-80.
17. Avis HJ, Hutten BA, Gagné C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010;55:1121-6.
18. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 1998;31:225-31.
19. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997;30:968-74.
20. Nazzaro P, Manzari M, Merlo M, et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999;33:719-25.
21. Borghi C, Dormi A, D'Addato S, et al. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J Hypertens 2004;22; 1707-16.
22. Rajagopalan S, Zannad F, Radauceanu A, et al. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 2007;100:222-6.
23. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31.
24. Egede R, Jensen LO, Hansen HS, et al. Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients. Int J Cardiol 2012;158:376-9.
25. Lewis TV, Cooper BA, Dart AM, Chin-Dusting JP. Responses to endotheliumdependent agonists in subcutaneous arteries excised from hypercholesterolaemic men. Br J Pharmacol 1998;124:222-8.
26. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999;33:234-41.
27. Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol 1995;75:582-6.
28. Savić V, Eržen B, Janić M, et al. Improvement of arterial wall characteristics by the low-dose fluvastatin and valsartan combination in type 1 diabetes mellitus patients. Diab Vasc Dis Res 2013;10:420-5.
29. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004;110:3687-92.
30. Roberts C, Torgerson DJ. Understanding controlled trials: baseline imbalance in randomized controlled trials. BMJ 1999;319:185.